| Literature DB >> 25497973 |
Robert J Plenter1, Todd J Grazia2, David P Nelson3, Martin R Zamora4, Ronald G Gill5, Biagio A Pietra6.
Abstract
Fas Ligand limits inflammatory injury and permits allograft survival by inducing apoptosis of Fas-bearing lymphocytes. Previous studies have shown that the CD4(+) T-cell is both sufficient and required for murine cardiac allograft rejection. Here, utilizing a transgenic mouse that over-expresses Fas Ligand specifically on cardiomyocytes as heart donors, we sought to determine if Fas Ligand on graft parenchymal cells could resist CD4(+) T-cell mediated rejection. When transplanted into fully immunocompetent BALB/c recipients Fas Ligand transgenic hearts were acutely rejected. However, when transplanted into CD4(+) T-cell reconstituted BALB/c-rag(-/-) recipients, Fas Ligand hearts demonstrated long-term survival. These results indicate that Fas Ligand over-expression on cardiomyocytes can indeed resist CD4(+) T-cell mediated cardiac rejection and suggests contact dependence between Fas Ligand expressing graft parenchymal cells and the effector CD4(+) T-cells.Entities:
Keywords: Fas Ligand; Rejection; Transplantation
Mesh:
Substances:
Year: 2014 PMID: 25497973 PMCID: PMC4298462 DOI: 10.1016/j.cellimm.2014.11.007
Source DB: PubMed Journal: Cell Immunol ISSN: 0008-8749 Impact factor: 4.868